Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab subcutaneous induction for moderately to severely active Crohn's disease
2024-516023-13-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Risankizumab subcutaneous induction with Placebo comparator (2 arms). Primary endpoints: CDAI clinical remission at Week 12 and Endoscopic response at Week 12. Planned start Jan 2025; status: authorised.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2024-516023-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516023-13-00.